Our team is pursuing novel, alternative approaches to treat childhood cancer. Our research includes areas such as adoptive immunotherapies, stem cell graft engineering and molecular targeting of cancers with nanoparticles and small anti-cancer molecules.
γδ T Cells for Adoptive Cancer Immunotherapies
Cancer immunotherapy uses components of the immune system to fight cancer. It is a treatment modality which attempts to harness the immune system to recognize attack and kill malignant cells. Immunotherapies can consist of the administration of tumor-specific antibodies, cytokines, or the infusion or transfer of immune cells, such as Natural Killer (NK) cells or tumor-specific, genetically modified T cells such as chimeric antigen receptor-modified T cells (CARs), to name a few approaches. A cell population our lab is specifically interested in using in the context of cancer immunotherapy is γδ T cells. γδ T cells only comprise about 3-6% of the human peripheral lymphocytes but are important for the primary response to infectious agents. We and others have shown that γδ T cells also have potent anti-leukemic and anti-tumor effects and appear to play a crucial role in cancer immunosurveillance. Interestingly, γδ T cells do not cause graft-versus-host disease and seem therefore specifically suitable for autologous or allogeneic immunotherapy approaches. Our lab is therefore pursuing research with regards to the biology of γδ T cell activation, in vivo and ex vivo expansion and activation for use in adoptive cancer immunotherapies.
Stem Cell Graft Design
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established, successful treatment modality for a variety of malignant and nonmalignant conditions such as high-risk leukemias and lymphomas and some otherwise fatal conditions. With current allogeneic transplant regimen, the prolonged period of profound immune deficiency which occurs after transplant until the immune system has functionally recovered leaves the patient at high risk for life-threatening infections. More importantly, it likely prevents the donor-derived immune system from mediating a critical graft-versus-leukemia/tumor effect at a crucial time when minimal residual disease could potentially be eradicated, and the patient cured. Therefore, our lab is working on the pre-clinical as well as translational design of grafts and transplant regimens that lead to fast engraftment, but also provide the patient immediately with potent and activated effector cells such as NK cell or γδ T cells to deliver a strong anti-tumor benefit and protect from potentially deadly infections.
The evolution of nanotechnology offers a new dimension to tumor-targeting strategies. Nanoparticles have gained increasing interest for medical applications due to features such as unusual optical or magnetic properties, high stability and biological compatibility, controllable morphology and size dispersion, and chemical surface functionalization. One of the greatest promises of tumor-targeted nanoparticles is their multifunctionality, i.e. the possibility of simultaneous imaging, drug delivery, and other therapeutic and diagnostic applications, such as localized hyperthermia elicited by alternating magnetic fields. For cancer treatment applications this approach requires either direct injection of particles into the tumor, or more practically and elegantly, the use of molecular probes, such as antibodies, that specifically guide the nanoparticles to the cancerous cell. Our team’s initiative is to develop a nanotechnology-based platform to treat pediatric cancers, specifically neuroblastoma, which is one of the most common pediatric solid tumors with a high mortality rate in advanced-stage disease.
Anti-cancer Phospholipid Ether Analogs for Molecular Targeting of Pediatric Solid Tumors
NM404, a novel phospholipid ether analog developed at UW, is a promising, tumor-targeting anti-cancer agent that interferes with important signaling pathways in neuroblastoma and other cancers. Radiolabeled derivatives can be used for diagnostic imaging and molecular radiotherapy. Our lab is investigating promising strategies to integrate NM404 in current pediatric cancer treatment approaches. Our preliminary data in a variety of solid tumors are promising, demonstrating anti-cancer effects also in rodent xenograft models, while maintaining a very favorable toxicity profile.
The following scholarly articles were published by Department of Pediatrics faculty and staff during February 2020: Affenzeller S, Wolkenstein K, Frauendorf H, Jackson DJ. Challenging the concept that eumelanin is the polymorphic brown banded pigment …March 5, 2020
Department of Pediatrics and Division of Hematology, Oncology & Bone Marrow Transplant Associate Professor, Mario Otto, MD, PhD, and Fellow, Nicholas Pytel, DO, were each awarded research grants from Hyundai Hope on Wheels, a nonprofit …September 30, 2019
Sean Rinella, MPH, an ICTR TL1-supported PhD student, working with mentorship from Christian Capitini, MD and Mario Otto, MD, PhD in their labs, has been selected as one of “40 Under 40 in Cancer” for …June 5, 2019
American Family Children’s Hospital, part of the University of Wisconsin Carbone Cancer Center in collaboration with Cellectar Biosciences, Inc., is the first site in the nation to offer CLR 131, a systemically delivered, targeted radiotherapeutic …April 1, 2019
A new preclinical research project led by Department of Pediatrics Assistant Professor Christian Capitini, MD, aims to strengthen the pipeline of immunotherapy treatment approaches for neuroblastoma, the third most common type of childhood cancer. The …September 5, 2018
- More News...